盐酸氟桂利嗪联合盐酸倍他司汀治疗血管痉挛性头痛

目的观察氟桂利嗪联合盐酸倍他司汀治疗血管痉挛性头痛的临床疗效和安全性。方法将220例血管性头痛患者随机分为A组和B组各组110例,两组均予氟桂利嗪5mg,2次/d,A组加服倍他司汀4mg,3次/d,分别于治疗前后观察临床症状及颅多普勒超声（TCD）检测。结果治疗后临床总有效率A组明星优于B组（P〈0.01）。结论氟桂利嗪联合盐酸倍他司汀治疗血管性头痛疗效明显优于氟桂利嗪。     

加热药枕配合倍他司汀在颈性眩晕急性期疗效观察及护理体会

目的：观察加热药枕配合倍他司汀在颈性眩晕急性期的疗效,分析其作用机理及护理方式。方法：纳入42例颈性眩晕急性期患者,以加热药枕外用配合倍他司汀静滴,观察其在治疗后0.5、1、2h的疗效。结果：治疗0.5h后42例患者中,治愈8例（19.05%）,显效12例（28.57%）,有效20例（47.62%）,无效2例（4.76%）,总体有效率95.24%,随着治疗时间延长,2h后总体有效率100%。结论：加热药枕配合倍他司汀能够早期缓解患者症状,同时临床护理方面要注重药枕温度的保持、改进外形等。     

天麻钩藤饮治疗后循环缺血性眩晕25例

目的研究天麻钩藤饮治疗后循环缺血性眩晕的临床效果。方法选取2015年10月—2016年10月在东港市中医院神经内科就诊的50例后循环缺血性眩晕的患者,随机分为试验组和对照组,对照组25例,采取甲磺酸倍他司汀治疗,试验组25例,在对照组的基础上使用天麻钩藤饮治疗,比较两组患者治疗后的血液黏稠度。结果试验组治疗后血液黏稠度优于对照组,差异有统计学意义(P0.05)。结论对后循环缺血性眩晕患者使用天麻钩藤饮治疗,可以明显降低患者的血液黏稠度。     

葛根素与培他啶治疗眩晕疗效比较

目的 比较葛根素与培他啶治疗眩晕的疗效.方法 65例眩晕患者,随机分为葛根素组32例,男性21例,女性11例,年龄32～72岁平均(52.3±12.5)岁,给予葛根素注射液500mg加入5%葡萄糖注射液250ml中,静脉点滴,1次/d;培他啶组33例,男性22例,女性11例,年龄32～74岁,平均(54.6±11.7)岁,培他啶组给盐酸培他啶注射液500ml静脉滴注1次/d;两组均连续治疗7d.结果 葛根素组总有效率93.7%,培他啶组总有效率94%,两组无显著差异,(P＞0.05).结论 葛根素治疗眩晕疗效与培他啶相相仿,但葛根据素更适用于伴高血压、冠心病的眩晕患者,值得临床推广应用.     

凯时(PGE1)联合倍他司汀治疗椎-基底动脉缺血性眩晕35例疗效观察

目的观察凯时联合倍他司汀治疗椎-基底动脉缺血性眩晕疗效。方法椎-基底动脉缺血性眩晕65例随机分为治疗组(35例)及对照组(30例);治疗组予倍他司汀40mg(加入0·9%生理盐水250mL中)联合凯时10μg(加入0·9%生理盐水250mL中)静脉滴注,1次/d,治疗10d。对照组予丹参30mL(加入0·9%生理盐水250mL中)联合脉络宁30mL(加入0·9%生理盐水250mL中)静脉滴注,1次/d,治疗10d。全部病例治疗前后均作经颅多普勒(TCD)检查。结果治疗标准按痊愈、好转,无效划分;治疗组分别为29,4,2例;总有效率为95%;对照组分别为18,4,8例,总有效率为73%(P<0·01)。结论凯时联合倍他司汀治疗椎-基底动脉缺血性眩晕的效果优于丹参联合脉络宁的治疗效果。     

倍他司汀联合盐酸氟桂利嗪治疗耳鸣的疗效研究

目的：对倍他司汀联合盐酸氟桂利嗪治疗耳鸣的疗效进行分析探讨。方法选取该院于2010年9月-2014年9月收治的102例耳鸣患者，将其随机分为对照组50例和观察组52例，其中对照组给予盐酸氟桂利嗪治疗，观察组患者给予倍他司汀联合盐酸氟桂利嗪治疗。治疗后评估两组的临床疗效、听力指标比较和不良反应。结果治疗后，观察组总有效率为96.2%，明显高于对照组总有效率的54.0%，两组差异有统计学意义(P<0.05)；治疗后，观察组的耳鸣程度、听力改善情况均明显优于对照组(P<0.05)；对照组和观察组均无严重性的不良反应出现，差异无统计学意义（P>0.05）。结论倍他司汀联合盐酸氟桂利嗪治疗耳鸣的疗效显著，并且无严重不良反应伴发，值得临床推广使用。     

Double-blind,Randomized, Multicenter Study Comparing the Effect of Betahistine and Flunarizine on the Dizziness Handicap in Patients with Recurrent Vestibular Vertigo

Objective --The aim of this double-blind, randomized, multicenter study was to compare the efficacy of betahistine dihydrochloride (BH) and flunarizine (FL) using the Dizziness Handicap Inventory (DHI), a validated self-assessment questionnaire that has not previously been used in a clinical trial to evaluate antivertigo drugs. Material and Methods --Patients with recurrent vertigo of peripheral vestibular origin and who were severely handicapped by vertigo were randomized to an 8-week course of treatment with oral BH 48 mg daily or oral FL 10 mg daily. The efficacy endpoints were the total DHI score and the physical, functional and emotional subscores. Results --Fifty-two patients completed the study. After 8 weeks of treatment the mean total DHI score and the physical subscore were significantly lower in the BH group compared to the FL group (7.5 and 3.6 points, respectively). The mean total DHI score as well as the three subscores decreased significantly after 4 and 8 weeks in both treatment groups. Conclusion --This study showed that at 8 weeks BH is significantly more effective than FL in terms of improving the total DHI score and the physical subscore. It was also established that the DHI is a useful and reliable method for evaluating the efficacy of antivertigo drugs.     

Development of novel sustained release matrix pellets of betahistine dihydrochloride: effect of lipophilic surfactants and co-surfactants

Sustained release matrix pellets of the freely water soluble drug, betahistine dihydrochloride (BH), were prepared using freeze pelletization technique. Different waxes and lipids (cetyl alcohol, beeswax, glyceryl tripalmitate (GTP) and glyceryl tristearate) were evaluated for the preparation of matrix pellets. A D-optimal design was employed for the optimization and to explore the effect of drug loading (X₁), concentration of lipophilic surfactant (X₂), concentration of co-surfactant (X₃) and wax type (X₄) on the release extent of the drug from matrix pellets. The entrapment efficiency (Y₁), pellet diameter (Y₂), and the percentage drug released at given times were selected as dependent variables. Results revealed a significant impact of all independent variables on drug release from the formulated pellets. The lipophilic surfactant significantly increased both the entrapment efficiency and the in vitro drug release and significantly decreased the pellet size. The optimized BH-loaded pellets were composed of 19.95% drug loading, 9.95% Span^® 80 (surfactant), 0.25% Capmul^® (co-surfactant) using glyceryl tripalmitate as a matrix former. The release profiles of the drug from hard gelatin capsule containing optimized pellets equivalent to 32?mg BH was similar to that of target release model for once-daily administration based on similarity factor. It could be concluded that a promising once-daily capsule containing sustained release pellets of BH was successfully designed.